Skip to content
Pharma Observatory a Scientist.com platform

Organization (Industry)

Fisher & Paykel Healthcare (New Zealand)

ClinicalTrials.gov lists Fisher & Paykel Healthcare (New Zealand) as lead sponsor of 85 trials. It has 1 approved asset.

NZ Industry Manufacturer
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

17 0 2004 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 14 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 12 in 2026 and about 10 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 14 already registered with a 2026 start date: at the cutoff, 4 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts.

This page covers Fisher & Paykel Healthcare (New Zealand): 85 lead-sponsored trials and 1 legal-entity registration.

Get the Fisher & Paykel Healthcare (New Zealand) report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (34)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Sleep Apnea Syndromes 74
Sleep Apnea, Obstructive 71
Pulmonary Disease, Chronic Obstructive 25
Respiratory Insufficiency 20
Hypercapnia 6

Trials by start year as sponsor or collaborator (22)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 14
2025 8
2024 4
2023 6
2022 9
2021 5
2020 6
2019 6
2018 6
2017 16

Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Approved assets (1)

Approved assets
Drug Trials
Acetaminophen 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
35% hit target (n=17) 80% on time (n=15)

Journals published in (52)

Shown in this order: most published in first.

Journals published in
Journal Publications
American journal of respiratory and critical care medicine 15
Chest 8
Respiratory care 8
The European respiratory journal 8
Critical care (London, England) 6

US granted patents (1)

Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.

US granted patents
US patents granted Granted in the last 5 years Most recent grant
1,233 609 2025-12-30

FDA inspection record (1)

FDA inspection record
Latest classification Inspections
NAI 2

FDA recalls (7)

Shown in this order: most recent first.

FDA recalls
Product Classification Initiated
Airvo 2, REF: PT101US, and myAirvo 2, REF: PT100US, used with Disinfection Kit User Manual, REF: UI-185043723 Class II 2025-09-18
PT301US Airvo 3 Respiratory Support Device with software version 1.2.0 and/or 1.5.1 The Airvo 3 is intended to provide high flow warmed and humidified respiratory gases for administration to spontaneously breathing infant, child, adolescent and adult patients in hospitals and sub-acute facilities. Class II 2024-08-07
Airvo 2 Humidifier, REF: PT101US, and myAirvo 2 Humidifier, REF: PT100US Class II 2024-04-02
Fisher and Paykel Healthcare (FPH) IW900-Series Infant Warmer Fisher and Paykel; Healthcare CosyCot and Kit Replacement Head Case Assembly It is designed to assist with the thermoregulation of infants weighing up to 10kg and is used by labor and delivery rooms and pediatric intensive care units. Infant Warmers Model Number (REF) IW910XXX, IW920XXX, IW931XXX, IW932XXX, IW933XXX, IW934XXX, IW951XXX, IW952XXX, IW953XXX, IW954XXX, IW980XXX, IW990XXX Spare Parts Model Number (REF) 043041129, 043041130, 043041131, 043042359, 648040142 Class II 2014-11-06
Infant Nasal CPAP (continuous positive airway pressure) Prong, Nasal. CPAP Prongs (10 pack): Model No. BC3020-10, BC3520-10, BC4030-10, BC4540-10, BC5040-10, BC5050-10, BC5550-10, BC5560-10, BC6060-10, BC6070-10, BC6570-10. Bubble CPAP Starter Kits: Model No. BC461-SK, BC471-SK, BC490-SK, BC491-SK, BC492-SK. The Nasal CPAP Prongs connect to the FPH FlexiTrunk Patient Interface. Class I 2014-04-15

FDA import refusals (1)

FDA import refusals
Refused import lines Latest refusal
11 2017-05-16

Manufacturing and distribution sites (1)

Manufacturing and distribution sites
Facility Location Regulators Member organization
FISHER & PAYKEL HEALTHCARE, LTD. EAST TAMAKI Auckland, NZ FDA

Organization relationships (18)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
Helios Klinik Ambrock Co sponsors trial with 2
Philips Respironics Co sponsors trial with 2
Adelaide Institute for Sleep Health Co sponsors trial with 1
Hospital do Coração Co sponsors trial with 1
Associação Fundo de Incentivo à Pesquisa Co sponsors trial with 1

Latest dated events (1,396)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-12-31 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-10-26 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-10 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-10-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-09-28 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (176)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
BTBD8 Trial collaborator Named in trial inclusion criteria
CROT Trial sponsor Named in trial inclusion criteria
MAP3K8 Trial sponsor Named in trial inclusion criteria
NAP1L1 Trial collaborator Named in trial inclusion criteria
NRP1 Trial collaborator Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.